'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies

Nicole DeFeudis

Editor

Scientists have been after the “Holy Grail” of cell therapy — an off-the-shelf product — for years. Notch Therapeutics is now joining the quest with a tech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'In­dus­tri­al­iz­ing the pro­duc­tion of cell­s': An­oth­er iP­SC play­er joins the quest for off-the-shelf cell ther­a­pies

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies